1. Trang chủ
  2. » Tất cả

2 drhue vdd mạn do hp 2eng ebmt 251116

29 4 0

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 29
Dung lượng 2,61 MB

Nội dung

EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN (EBMT) in patients with H pylori- related chronic gastritis Dang Ngoc Quy Hue Tran Van Huy Nguyen Thanh Hai Hue Univesity of Medicine and Pharmacy ThongNhat – DongNai General Hospital CONTENT BACKGROUND AIMS SUBJECTS AND METHODS RESULTS - DISCUSSION CONCLUSION - SUGGESTION 1.BACKGROUND • H pylori- related chromic gastritis  the strongest risk factor for gastric cancer  Maastricht IV & V: eradication of H pylori = primary prevention of GC Challenges: +++ •  increased quickly rate of resistance of H pylori • Correa, P (1992) Cancer research 52: 6735-6740 • Fallone, C A., et al (2016), The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults, Gastroenterology • Malfertheiner, P., et al (2012, 2016), Management of Helicobacter pylori infection the Maastricht IV, V Gut 1.BACKGROUND Resistant rate (%) Author Resistance Year CLR Bình T.T LFX MTZ 2008 33.0 18.4 69.9 Phan Trung Nam 2012-2013 42.9 30.2 84.6 44.6 39.5 61.5 Đặng Ngọc Quý Huệ 2013 71.6 64.1 30.6 29.2 TET AMX ≥2 ABX CLR+MTZ 24.3 5.8 0.0 67.9 67.4 69.2 - 1.8 0.0 7.7 abx 45.6 - - - CLR+LFX 22.4 1.BACKGROUND • Maastricht IV (2012), V (2016), Toronto (2016): bismuth – containing quadruple therapy (PBMT)  first-line empirical treatment and after the first eradication failure • Data about eradication rates of PBMT in Vietnam: still limited • Fallone, C A., et al (2016), The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults, Gastroenterology • Malfertheiner, P., et al (2012, 2016), Management of Helicobacter pylori infection the Maastricht IV, V Gut AIMS  To evaluate Helicobacter pylori eradication rate  To determine the rate of side effects  To access the rate of medication compliance  of bismuth-containing quadruple regimen (EBMT) in patients with chronic gastritis H pylori (+) 3.SUBJECTS AND METHODS • STUDY DESIGN Prospective, uncontrolled clinical trial • POPULATION Outpatient with gastroduodenal disease followed up at Gastroenterology clinics, in Thong Nhat – Dong Nai General Hospital 3.PATIENTS • INCLUSION CRITERIA  Signs, symptoms of gastroduodenal disease  Endoscopy: purely gastritis  Histology: chronic gastritis  Diagnosis in H pylori infected by ≥ tests (+): RUT (+) + 100% 1/3 - Antrum biopsy specimen - Corpus biopsy specimen H pylori (+) - Culture 3.PATIENTS • EXCLUSION CRITERIA  Used: Antibiotics, Bismuth < wks; anti-secretory agents < wks  Medical history: Coagulation disorders, allergy to any drugs  Chronic disease: heart failure, renal failure, cirrhosis, chronic pulmonary disease  Laboratory test:  PLT < 100 K/L  ALT > 60UI/L (male), > 38 UI/L (female)  Gastric histopathology with cancer cells ERADICATION REGIMEN • ERADICATION REGIMEN EBMT 10 days: Esomeprazol 40 mg, b.i.d; 30 mins before meal Tripotassium dicitrato Bismuthate 600 mg, b.i.d; 30 mins before meal Metronidazole 250 mg, q.i.d Tetracycline 500 mg, q.i.d 10 4.DEMOGRAPHIC VARIABLES Mean age Female (%) Dore [1] 52 62.33 Laine [2] 47±13 38 Malfertheiner [3] 48.53±14.64 48 Our study 38.70± 10.47 42.77 Author • Our study: purely chronic gastritis, included nạve patients or after ≥ one eradication failure • Other studies: imflammation, ulcers and other gastroduodenal disease, naïve patients (1) Dore, M P., et al (2011), Helicobacter, 16(4), pp.295-300 (2) Laine, L., et al (2003), Am J Gastroenterol, 98(3), pp.562-567 (3) Malfertheiner, P., (2011), Lancet, 377(9769), pp.905-913 15 4.HISTORY OF TREATMEN H PYLORI 16 4.SUCCESSFUL OF H PYLORI ERADICATION RATE RESULTS OF H PYLORI ERADICATION POPULATION ITT (n = 166) PP (n = 150) Cases (%) CI 95% Cases (%) CI 95% Overall 134 (80.72) 73.89 – 86.43 134 (89.33) 83.26 – 93.78 Naïve patients 97 (79.51) 71.25 – 86.28 97 (90.65) 83.48 – 95.43 22 (91.67) 73.00 – 98.97 22 (91.67) 73.00 – 98.97 15 (75.00) 50.90 – 91.34 15 (78.95) 54.43 – 93.95 After 1st eradication failure After ≥ eradication failures 17 4.RATE OF FIRST H.PYLORI ERADICATION NAÏVE PATIENTS RESULTS OF H PYLORI ERADICATION Author ITT (%) PP (%) Dore [1] 92 95 Laine [2] 87.7 92.5 94 98 79.51 90.65 O’Morain [3] Our study •Don’t know clearly the importance of H pylori eradication •Be afraid of endoscopy after H pylori treatment •Choose urea breath test (1) Dore, M P., et al (2011), Helicobacter, 16(4), pp.295-300 (2) Laine, L., et al (2003), Am J Gastroenterol, 98(3), pp.562-567 (3) O'Morain, et al (2003), Aliment Pharmacol Ther, 17(3), pp.415-420 18 4.RATE OF H PYLORI ERADICATION AFTER 1ST ERADICATION FAILURE Author RESULTS OF H PYLORI ERADICATION ITT (%) PP (%) T T Trung [1] 93.3 95.7 Kuo [2] 79.7 90.8 91.67 91.67 Our study •Successful eradication: T T Trung > Our study > Kuo •Result of Kuo’s study after 1st eradication failure (ITT 79.7 and PP 90.8%) is the same as the first eradication result in our study (79.51 and 90.65%)  given up treament (1) Trần Thiện Trung (2009), Y học Tp Hồ Chí Minh, 13(Phụ số 1), tr.11-17 (2) Kuo, C H., et al (2013), J Antimicrob Chemother, 68(1), pp.222-228 19 4.RATE OF H PYLORI ERADICATION AFTER ≥ ERADICATION FAILURES Author Gisbert Our study RESULTS OF H PYLORI ERADICATION ITT (%) PP (%) 65 67 75.00 78.95 •Gisbert: •Treatment duration varied from to 14 days •Variable doses of Tetracycline Metronidazole (1) Gisbert, J P., (2014), Dig Dis Sci, 59(2), pp.383-389 20 ... Author ITT (%) PP (%) Dore [1] 92 95 Laine [2] 87.7 92.5 94 98 79.51 90.65 O’Morain [3] Our study •Don’t know clearly the importance of H pylori eradication •Be afraid of endoscopy after H pylori... patient Treatment EBMT D1-D10 FLOW – CHART OF THE STUDY patients excluded: lost to follow-up 16 patients excluded : -3 side effects -1 unrelieved disease -2 compliance

Ngày đăng: 31/01/2023, 13:43